Descovy (Emtricitabine/Tenofov Alafenam) Patent Expiration, LOE Window & CMS Spending

Descovy (Emtricitabine/Tenofov Alafenam) by Gilead Sciences: FDA Orange Book core substance LOE 2033-02-15 (last listed 2036-06-29), 2 AB generics, $1.02B 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGilead Sciences
FDA Application & PathwayN208215 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2033-02-15
Last Listed Patent or Exclusivity Date2036-06-29
Orange Book Patents (*PED Extensions)8 patents (2 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$1.02B
2024 Medicare Part D Spend$544.7M
2024 Medicaid Spend$470.3M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 17.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.